By a News Reporter-Staff News Editor at Biotech Week -- Pharmaceutical executives and leaders in biotech are on board to speak at the 19th annual BIO-EuropeŽ international partnering conference in Vienna, Austria, November 4-6, 2013. Organized by EBD Group in collaboration with the Biotechnology Industry Organization and local host Life Science Austria Vienna (LISAvienna), the event is Europe's largest partnering conference serving the global biotechnology industry (see also EBD Group).
The event is built upon the one-to-one partnering meetings powered by the life science industry's leading networking solution, partneringONEŽ. With partneringONE, partnering meetings at BIO-Europe in Vienna can be scheduled prior to the event, and will be the main focus of activity on site. BIO-Europe also features a robust program focused on topics relevant to industry executives, and ranges from panels and workshops to keynote addresses and industry presentations.
The high caliber of executive speakers from the life sciences, complemented with timely program topics, draws delegates to BIO-Europe every year. In 2012, the Hamburg, Germany edition was attended by 2,957 delegates representing 52 countries. Delegates had access to 3,028 projects available for partnering, and over 15,000 one-to-one partnering meetings were held.
Parallel workshops kick off the first day, and topics range from collaborative approaches to translational research, to licensing issues and nano-therapeutics. Stefan Frings, Global Head of Oncology/Immuno-Oncology at Roche Partnering, is a panelist on "Personalized medicine in oncology: Turning away from the 'one size fits all' therapy?" taking place Monday morning, November 4. "A personalized approach to drug treatment is an important improvement to cancer patient outcomes," said Frings. "But the slow pace of getting customized treatments, including the associated diagnostic from bench to bedside and to be embraced by payers, is an issue. At BIO-Europe, leaders in oncology will come together to discuss personalized medicine and its application to the future of cancer research."
A big draw every year are the parallel panel discussions in the Spotlight and Business Development Tracks. James O'Mara, VP, Corporate Development at Ironwood Pharmaceuticals is a panelist on "How to position your asset for the optimal deal," to take place on Monday afternoon. "The barometer of success is always the deal. Did you get the deal and how much was it worth?" said O'Mara. "But the real question is what has the deal done for your company? If you don't have a compelling answer to that question then you have done the wrong deal."
The second day features a Keynote plenary entitled "A day in the life of experienced dealmakers: Transformational deals that shaped the industry in 2013" with panelists from big pharma. Panelist James Sabry, Senior VP and Global Head of Genentech Partnering, said, "There was significant deal activity in the first quarter of 2013, and these were driven by several large transactions. This was followed by a 'quality over quantity' trend where we have seen less deal value but increased innovation. We will review that activity and discuss the outlook for the fourth quarter and 2014 especially in light of the current IPO market."